Vertex Net Income

VRTX
 Stock
  

USD 316.86  1.56  0.49%   

Vertex Pharmaceutic fundamentals help investors to digest information that contributes to Vertex Pharmaceutic's financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceutic stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Vertex Pharmaceutic Net Income is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Net Income of 2.34 Billion in 2021. Net Income to Non Controlling Interests is likely to rise to about 27.2 M in 2022, whereas Net Income Common Stock is likely to drop (139 M) in 2022.

Vertex Net Income Analysis

Vertex Pharmaceutic's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Vertex Pharmaceutic Net Income

2.53 Billion

Net Income 
 = 
(Rev + Gain) 
-  
(Exp + Loss) 
More About Net Income | All Equity Analysis

Current Vertex Pharmaceutic Net Income

    
  3.27 B  
Most of Vertex Pharmaceutic's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceutic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Vertex Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceutic is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Net Income. Since Vertex Pharmaceutic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceutic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceutic's interrelated accounts and indicators.

Vertex Net Income Historical Pattern

Today, most investors in Vertex Pharmaceutic Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vertex Pharmaceutic's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's net income growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vertex Pharmaceutic net income as a starting point in their analysis.
   Vertex Pharmaceutic Net Income   
Share
       Timeline  
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Compare to competition

Vertex Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

20.56 Million

Vertex Pharmaceutic Accumulated Other Comprehensive Income is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Accumulated Other Comprehensive Income of 19.06 Million in 2021
Based on the recorded statements, Vertex Pharmaceutic reported net income of 3.27 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net income for all United States stocks is significantly lower than that of the firm.

Vertex Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceutic's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceutic could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceutic by comparing valuation metrics of similar companies.
Vertex Pharmaceutic is currently under evaluation in net income category among related companies.

Vertex Pharmaceutic Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vertex Pharmaceutic from analyzing Vertex Pharmaceutic's financial statements. These drivers represent accounts that assess Vertex Pharmaceutic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vertex Pharmaceutic's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee114.56 K838.76 K392.27 K795.36 K600.54 K647.95 K
Revenue Per Employee1.08 M1.22 M1.39 M1.82 M1.94 M2.1 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA103.26 M706.76 M1.5 B3.26 B2.91 B3.14 B

Vertex Pharmaceutic ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceutic's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceutic's managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Vertex Pharmaceutic Institutional Holders

Institutional Holdings refers to the ownership stake in Vertex Pharmaceutic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceutic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceutic's value.
Security TypeSharesValue
Zwj Investment Counsel IncCommon Shares1.9 K445 K
Zwj Investment Counsel IncCommon Shares1.9 K409 K
Zweigdimenna Associates LlcCommon Shares54.1 K11.6 M
Zweigdimenna Associates LlcCommon Shares151.2 K19 M
Zweigdimenna Associates LlcCommon Shares162.2 K19.3 M
Zweigdimenna Associates LlcCommon Shares98.8 K7.9 M
Zurich Insurance Group LtdCommon Shares46.9 K7.9 M

Vertex Fundamentals

About Vertex Pharmaceutic Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Net Income2.3 B2.5 B
Net Income Common Stock-128.9 M-139 M
Net Income to Non Controlling Interests25.2 M27.2 M
Net Income Per Employee600.5 K647.9 K

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceutic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at Vertex Pharmaceutic Piotroski F Score and Vertex Pharmaceutic Altman Z Score analysis. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.095
Market Capitalization
80.3 B
Quarterly Revenue Growth YOY
0.18
Return On Assets
0.14
Return On Equity
0.29
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.